6 Top Gainers In Healthcare Sector (ATOS, AKTX, ATHX...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Atossa Genetics Inc. (ATOS)

Atossa Genetics is a clinical-stage biopharmaceutical company developing novel therapeutics for breast cancer and other breast conditions.

Gained 22.97% to close Tuesday's (Apr.23) trading at $3.48.

News: No news

Pipeline:

Atossa has two development programs: Endoxifen (topical and oral forms) and a program for the targeted delivery of drugs and immunotherapies via its proprietary intra ductal microcatheters to treat early breast cancer.

Clinical Trials:

-- A phase II study to determine if Oral Endoxifen reduces tumor activity in early stage breast cancer patients in the "window of opportunity" between diagnosis of breast cancer and surgery. -- A phase II study to determine if Topical Endoxifen reduces mammographic breast density, or MBD (enrollment completed in Sweden). -- A completed phase I study of Topical Endoxifen in men that supports further development in men with gynecomastia induced by androgen deprivation therapy. -- A phase II study of Topical Endoxifen to treat gynecomastia in men being treated with androgen deprivation therapy for prostate cancer. -- A phase II study of Oral Endoxifen in Tamoxifen refractory breast cancer patients.

Near-term Catalyst:

The Company's President and CEO, Steven Quay, is scheduled to make a presentation titled" A Twenty-First Century Approach: From Primary Prevention to Intraductal Immunotherapy" on April 25 at the Precision Breast Cancer World R&D Summit.

2. X4 Pharmaceuticals Inc. (XFOR)

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases.

Gained 21.52% to close Tuesday's trading at $19.14.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase II open-label extension study of Mavorixafor for the treatment of patients with WHIM syndrome is ongoing. -- A blinded phase III pivotal trial of Mavorixafor for the treatment of patients with WHIM syndrome is expected to commence in the second quarter of 2019. -- A phase I clinical trial of Mavorixafor for the treatment of patients with severe congenital neutropenia is anticipated to commence in 2019. -- A multi-national phase I/II clinical trial of Mavorixafor in combination with ibrutinib for the treatment of patients with Waldenström macroglobulinemia is expected to commence in 2019. -- Enrollment in the open-label phase IIa portion of the ongoing phase I/II clinical trial of Mavorixafor in combination with axitinib in clear cell renal cell carcinoma (ccRCC) patients has been completed. The Company plans to unveil progression-free survival (PFS) data as part of an anticipated abstract to be submitted for presentation at a major medical conference in the second half of 2019.

3. Immunic Inc. (IMUX)

Immunic is a clinical-stage biopharmaceutical company developing oral immunology therapies for chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis.

Gained 21.33% to close Tuesday's trading at $17.35.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase II study of IMU-838 for ulcerative colitis is underway, with interim dosing analysis expected in mid-2019, and full data readout expected in Q2 2020. -- A phase II study of IMU-838 for relapsing-remitting multiple sclerosis is ongoing, with unblinded data expected to be reported in 2021. -- A phase II study of IMU-838 in Crohn's disease is anticipated to begin in Q3 2019. -- A phase I trial of IMU-935 in healthy volunteers and psoriasis patients is expected to begin in Q3 2019. -- A phase I trial of IMU-856 is expected to begin in H1 2020. IMU-856 targets inflammatory bowel diseases, including ulcerative colitis and Crohn's disease.

4. Trovagene Inc. (TROV)

Trovagene is a clinical-stage oncology therapeutics company.

The Company's lead product candidate is Onvansertib being tested in combination with either low-dose cytarabine (LDAC) or decitabine for the treatment of Acute Myeloid Leukemia (AML) under a phase Ib/II trial, and in combination with Zytiga for the treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) in a phase II trial.

Gained 17.74% to close Tuesday's trading at $3.85.

News: The Company announced preclinical data that demonstrated the *synergy of combining Onvansertib with Venetoclax in an Acute Myeloid Leukemia cell model known to be resistant to Venetoclax.

*Synergy means the combined effect of the two drugs is greater than the sum of their individual effects.

5. Athersys Inc. (ATHX)

Athersys is a clinical-stage biotechnology company, with a focus in the field of regenerative medicine.

The Company is developing its MultiStem cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, for neurological, cardiovascular, and inflammatory and immune diseases.

Gained 16.08% to close Tuesday's trading at $1.66.

News: The Company's partner HEALIOS K.K. has enrolled the first patient in its ONE-BRIDGE study in Japan, evaluating MultiStem cell therapy treatment of patients who suffer from acute respiratory distress syndrome.

This trial will enroll 30 patients - with 20 subjects receiving MultiStem cell therapy treatment and standard of care and 10 subjects receiving standard therapy alone.

Acute respiratory distress syndrome, or ARDS, occurs in critically ill patients, wherein fluid leaks into the lungs making breathing difficult or impossible. (Source: American Lung Association).

6. Akari Therapeutics Plc (AKTX)

Akari Therapeutics is a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases.

The Company's lead product candidate is Nomacopan (Coversin).

Gained 15.82% to close Tuesday's trading at $3.88.

News: The Company announced positive initial Phase II clinical data of Coversin from the first three of bullous pemphigoid (BP) patients in an ongoing clinical trial.

Bullous pemphigoid is a severe orphan inflammatory skin disease currently treated primarily with steroids and immunosuppressants.

According to the Company, initial results from the first three patients showed that Nomacopan (Coversin), dosed daily subcutaneously, was well tolerated in three elderly patients (over 65 years of age), and that there were no drug-related adverse events.

Near-term Catalyst:

Interim data from a phase I/II clinical trial of Coversin in atopic keratoconjunctivitis (AKC), a rare and chronic form of eye allergy, is expected to be presented on April 28, 2019.